Study drug for advanced KRAS G12C solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid cancer that is advanced (metastatic or locally advanced) and is getting worse
- Your tumor test (from tissue or blood) shows a KRAS G12C mutation within the last 5 years
- Your cancer has measurable spots doctors can track on scans
- You are well enough to function day-to-day (ECOG 0 or 1)
- Your blood and organ tests are adequate, based on the trial’s screening window
- You have not recently received other cancer treatments without enough time to “wash out,” per the protocol
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Hear when a new KRAS P.G12C trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.